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Abstract
Background. The objective of the study was to evaluate the prevalence of metabolic syndrome (MS) in male popu-
lation of the Warmia and Masuria region in Poland according to IDF 2005 recommendations. 
Material and methods. 631 men, aged 19–82 years (mean 47 ± 14) were examined between Dec 2014 and Dec 
2016. Standardized questionnaire was completed by the subjects. Anthropometric measurements were performed. 
Blood pressure was measured. Blood tests (serum fasting glucose, lipidogram) were performed in 398 men (age: 48 
± 13years). Following age groups were identified: < 30YOA, 30–47YOA, 48–64YOA, ≥ 65YOA. Two groups of 398 
men were defined: MS+ who fulfilled MS criteria, MS- who did not fulfill MS criteria.
Results. MS was diagnosed in 45.7% of 398 men. There was a significant age-related increase in its prevalence: < 
30years of age (YOA) 9.5%, 30–47YOA 38.1%, 48–64YOA 53.2%, ≥ 65YOA 65.8%. Prevalence of components of 
MS in study group (n = 398) was: waist circumference (≥ 94 cm) in 254 (63.8%); high triglycerides (≥ 150 mg/dl or 
hypertriglyceridemia treatment) in 146 (36.7%); low HDL (< 40 mg/dl or dyslipidemia treatment) in 83 (20.9%); 
fasting glucose (≥ 100 mg/dl or diabetes treatment) in 173 (43.5%); elevated blood pressure (SBP ≥ 130 mmHg or 
DBP ≥ 85 mmHg or treatment of hypertension) in 313 (78.6%). 
Conclusions. The prevalence of MS in male population of Warmia and Masuria was 45.7% with significant increase 
in age. The study confirms the necessity of early prevention of MS in that region of Poland. 
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Streszczenie 
Wstęp. Celem pracy była ocena częstości występowania zespołu metabolicznego (MS) według zaleceń IDF 2005 
wśród mężczyzn w województwie warmińsko-mazurskim.
Materiał i metody. Zbadano 631 mężczyzn w wieku 19–82 lat. Dane zebrano między XII 2014 r. a XII 2016 r. 
Każdy z badanych wypełnił standaryzowany kwestionariusz. Dokonano pomiarów antropometrycznych. Zmierzo-
no ciśnienie tętnicze. W surowicy 398 mężczyzn (wiek: 48 ± 13) zbadano poziom glukozy i lipidogram. Analizy 
przeprowadzono dla czterech grup wiekowych: < 30, 30–47, 48–64, ≥ 65 lat. Wyodrębniono grupy: MS+ badani 
spełniali kryteria MS oraz MS- badani nie spełniali tych kryteriów. 
Wyniki. MS rozpoznano u 45,7% badanych. Zaobserwowano istotny wzrost częstości występowania MS w grupach 
wiekowych: < 30 lat 9,5%, 30–47 lat 38,1%, 48–64 lat 53,2%, ≥ 65 lat 65,8%. Częstość występowania kryteriów 
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MS (n = 398) wyniosła: obwód talii (≥ 94 cm) u 254 badanych (63,8%); stężenie triglicerydów (≥ 150 mg/dl lub 
leczenie hipertriglicerydemii) u 146 (36,7%); HDL (< 40 mg/dl lub leczenie dyslipidemii) u 83 (20,9%); glukoza 
na czczo (≥ 100 mg/dl lub leczenie cukrzycy) w 173 (43,5%), podwyższone ciśnienie tętnicze (SBP > 130 mmHg 
lub DBP ≥ 85 mmHg lub leczenie nadciśnienia tętniczego) u 313 (78,6%).
Wnioski. Częstość występowania MS wśród populacji męskiej Warmii i Mazur wynosiła 45.75% i wykazywała 
istotny wzrost z wiekiem. Wyniki potwierdzają konieczność wczesnego wykrywania MS u mężczyzn w tym regionie 
Polski.
Słowa kluczowe: zespół metaboliczny, prewalencja, populacja mężczyzn
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Introduction
According to the IDF 2005 definition of metabolic 
syndrome (MS) it is a cluster of cardiovascular risk 
factors which are considered to be strong predictors 
for the disease [1]. Abdominal obesity is one of the 
major underlying contributors to the MS [2]. For 
MS diagnosis, waist circumference depending on 
gender and race as well as two of four additional 
criteria have to be fulfilled. The cut-points criteria 
for IDF 2005 MS definition are: waist circumference 
for Europids ≥ 94 cm in male and ≥ 80 cm in female, 
triglycerides ≥ 1.7 mmol/l (150 mg/dl) or hyper-
triglyceridemia treatment, HDL-cholesterol < 1.03 
mmol/l (40 mg/dl) in males, < 1.29 mmol/L (50 mg/
dl) in females or dyslipidemia treatment, SBP ≥ 130 
mmHg or DBP ≥ 85 mmHg or treatment of arterial 
hypertension, fasting plasma glucose ≥ 5.6 mmol/l 
(100 mg/dl) or treatment of type 2 diabetes [1].
Despite significant progress in the field of pre-
ventive healthcare, prevalence of MS and its clinical 
consequences are rapidly increasing [3]. Incorrect 
dietary habits and low physical activity are only some 
of the reasons for higher risk of metabolic abnormal-
ities. Based on the results of WOBASZ study, it was 
found that the percentage of adult Poles with MS was 
30.7% in men and 26.8% in women [4].
In Poland Warmia and Masuria region is character-
ized by the smallest proportion of people with the age 
of 65 years and more [5]. The objective of the study 
was to evaluate the prevalence of MS in male popula-
tion of Warmia and Masuria region. The results may 
be crucial for the prevention efforts in the future. 
Material and methods
ProM (Pro Men) Project is conducted by the Faculty 
of Medical Sciences at University of Warmia and 
Mazury. Between Dec 2014 and Dec 2016, 631 
men from Warmia and Masuria region aged 19–82 
(mean 47.2 ± 13.7) years were examined. Each sub-
ject signed an informed consent to participate in the 
project. The study protocol was approved by the eth-
ics committee of the Regional Medical Chamber of 
Warmia and Mazury. The study was conducted with 
respect to guidelines of Good Clinical Practice. Stan-
dardized questionnaire with questions about lifestyle, 
physical activity, comorbidity and cardiovascular risk 
factors was completed for the subjects. Comorbidities 
study included presence or absence of arterial hyper-
tension, diabetes mellitus, dyslipidemia. Anthropo-
metric measurements were performed. In according to 
ESH/ESC guidelines [6], arterial blood pressure was 
measured 4 times by Omron M3/Japan, twice both 
on the left and right arm at an interval of 10 minutes. 
For statistical analysis, the second averaged measure-
ment from the left and right arm were selected. 398 
out of 631 men measured serum fasting glucose and 
lipidogram in a  certified laboratory. Following age 
groups were identified in our study sample: < 30YOA, 
30-47YOA, 48-64YOA, ≥ 65YOA. Two groups of 
398 men were defined: MS+ who fulfilled MS criteria, 
MS- who did not fulfill MS criteria.
Statistical analysis was performed using the SPSS 
v.23 software (IBM Corp./USA). Data were com-
pared using the chi-quadrat test, non-parametric test 
for 2-unpaired samples (Mann-Whitney U test) and 
Kruskal-Wallis test for k-unpaired samples. A p value 
of less than 0.05 was considered statistically signifi-
cant. The confidence intervals (CI) were 95%. 
Results
45.7% of 398 men with measured values of serum 
fasting glucose and lipidogram fulfilled the MS cri-
teria. The number of MS+ and MS- differed not sig-
nificantly (pchi–quadrat = 0,088). Detailed characteristics 
of the study group are listed in Table I and Table II.
The prevalence of MS increased with age (p < 
0.001, Kruskal-Wallis test) (Fig.1). 
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table I. Clinical data of the study group. Parameters are presented as mean ± standard deviation. For metabolic syndrome criteria p value 
were not calculated
Parameters All
N = 398
MS-
N = 216
MS+
N = 182 
p
Mann Whitney test
Age 48.22 ±12.53 45.38 ± 12.81 51.58 ± 11.33 < 0.001
Waist circumference [cm] 98.04 ± 12.11 91.47 ± 10.85 105.78 ± 8.38 —
SBP [mmHg] 137.25 ± 17.06 130.91 ± 14.36 144.77 ± 16.99 —
DBP [mmHg] 88.92 ± 10.92 85.05 ± 9.86 93.52 ± 10.34 —
Triglycerides [mg/dl] 141.16 ± 93.82 105.66 ± 61.43 183.30 ± 107.39 —
HDL-cholesterol [mg/dl] 52.11 ± 13.99 57.75 ± 13.30 45.41 ± 11.67 —
Glucose [mg/dl] 100.46 ± 23.67 93.08 ± 14.21 109.19 ± 29.09 —
Heart rate [bpm] 48.33 ± 11.06 45.87 ± 9.48 51.26 ± 12.08 0.001
Pulse pressure [mmHg] 72.60 ± 10.66 70.78 ± 10.43 74.76 ± 10.55 < 0.001
SBP — systolic blood pressure; DBP — diastolic blood pressure, glucose — serum fasting glucose; triglycerides and HDL-cholesterol were measured in serum
table II. Clinical data of the study population in age groups. Parameters are presented as mean ± standard deviation
Parameters < 30
n = 21
30–47
n = 168
48–64
n = 171
≥ 65
n = 38
p
Kruskal Wallis test
Waist circumference [cm] 90.8 ± 11.3 96.4 ± 12.6 100.5 ± 10.9 102.7 ± 11.8 < 0.001
SBP [mmHg] 129.8 ± 12.3 132.2 ± 14.0 139.2 ± 17.8 144.7 ± 18.0 < 0.001
DBP [mmHg] 79.2 ± 8.3 87.5 ± 10.5 89.9 ± 10.8 88.2 ± 10.5 0.002
Triglycerides [mg/dl] 112.3 ± 75.9 139.2 ± 96.0 146.3 ± 87.9 142.4 ± 116.8 0.047
HDL-cholesterol [mg/dl] 55.1 ± 13.7 52.0 ± 14.5 51.8 ± 13.0 52.4 ± 16.2 0.71
Glucose [mg/dl] 88.9 ± 9.7 93.1 ± 12.1 106.7 ± 29.7 110.4 ± 23.4 < 0.001
Pulse pressure [mmHg] 50.6 ± 11.2 44.7 ± 8.0 49.3 ± 11.7 56.5 ± 12.4 < 0.001
Heart rate [bpm] 73.8 ± 10.3 73.3 ± 10.6 72.0 ± 11.1 71.1 ± 11.5 0.24
SBP — systolic blood pressure; DBP — diastolic blood pressure, glucose — serum fasting glucose; triglycerides and HDL-cholesterol were measured in serum
Figure I. The prevalence of metabolic syndrome according to age Figure II. Waist circumference in age groups.
Figures 2–7 show the mean values of MS criteria 
in age groups.
Waist circumference, systolic blood pressure and 
serum fasting glucose level increased with age (p < 
0.001, Kruskal-Wallis test). 
The MS criterion fulfilled with the highest preva-
lence both in MS+ and MS- was SBP ≥ 130 mmHg 
or DBP ≥ 85 mmHg or treatment of hypertension (n 
= 172, 95%; n = 141, 65% respectively). The tenden-
cy was observed in all age groups. 100% of the MS+ 
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Figure III. Systolic blood pressure in age groups
Figure IV. Diastolic blood pressure in age groups
Figure V. Triglycerides level in age groups
Figure VI. HDL-cholesterol level in age groups
Figure VII. Fasting plasma glucose level in age groups
subjects with the age of 65 years and more fulfilled 
the discussed criterion. 96% (n = 24) of MS+ ≥ 65 
years subjects were treated for diabetes type 2 or had 
elevated serum fasting glucose (Tab. III).
discussion
The prevalence of MS in study population was 
45.7%. This is much higher than the results obtained 
in WOBASZ study where the MS (IDF criteria) was 
found in 30.7% of men in Poland [4]. Different 
analyses in Europe and around the world also showed 
lower rates of subjects with diagnosed MS (according 
to the IDF definition): 28.5% of men in Spain [7], 
39.9% of men in USA [8]. 
The comparison of data is complicated by the 
fact of using different definitions of MS. Several 
population studies have reported an increase in the 
prevalence of the MS with age regardless of the used 
criteria [9]. 
In WOBASZ [4] study mean waist circumfer-
ence in MS+ was 106cm, in MS- 90.6 cm. Re-
sults in our investigation (mean waist circumference 
in MS+ 105.7 cm, in MS- 97.5 cm) stay in agree 
with WOBASZ. SBP, DBP, serum fasting glucose, 
HDL-cholesterol in our study correspond with 
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table III. Prevalence of MS fulfilled criteria in age groups. Data are presented as numbers and  percentages of examined patients
Fulfilled MS criteria All < 30 30–47 48–64 ≥ 65
n = 398 MS+
n = 182
MS-
n = 216
MS+
n = 2
MS-
n = 19
MS+
n = 64
MS-
n = 104
MS+
n = 91
MS-
n = 80
MS+
n = 25
MS-
n = 13
Waist circumference 254
64%
182
100%
72
33%
0 5
26%
64
100%
31
30%
91
100%
31
39%
25
100%
5
38%
Triglycerides 146
37%
114
63%
32
15%
0 4
21%
44
69%
15
14%
54
59%
12
15%
15
60%
1
8%
HDL-cholesterol 83 
21%
70
38%
13
6%
0 1
5%
28
44%
7
7%
31
34%
3
4%
10
40%
24
15%
SBP or DBP 313 
79%
172
95%
141
65%
0 14
74%
59
92%
54
52%
86
95%
63
79%
25
100%
10
77%
Glucose 173 
44%
122
67%
51
24%
0 3
16%
28
44%
17
16%
70
77%
24
30%
24
96%
7
54%
SBP — systolic blood pressure; DBP — diastolic blood pressure
WOBASZ data and differ < 5%. We observe higher 
triglycerides both in MS+ (by 20%) and MS- (by 
8%) in comparison to WOBASZ.
The most prevalent MS criterion fulfilled by the 
subjects was elevated blood pressure or treatment 
of arterial hypertension. It was diagnosed in 78.6% 
of the subjects which corresponds to data obtained 
in the Norwegian HUNT2 study — 72.8% [10]. 
A  comparison of the prevalence of the other com-
ponents of MS between HUNT2 and ProM study 
show similar results for triglycerides level: it was 
36.7% in ProM and 33.3% in HUNT2 study. Waist 
circumference criterion was fulfilled by 42% of men 
in HUNT2 survey. It was 20% lower than in Warmia 
and Masuria region.
The prevalence of the low HDL-cholesterol cri-
terion is lower in our study: 20.9% to 28.3% in 
HUNT2. We observe higher prevalence of elevated 
glucose level: 43.5% in ProM vs. 32.7% in HUNT2. 
The results obtained in the ProM project indicate 
a higher prevalence of MS in men in Warmia and 
Masuria than in male population of Poland. The 
further study to understand the reasons of the phe-
nomenon should be concerned. The study confirms 
the necessity of early prevention of MS in that region 
of Poland.
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